Synergy CHC Corp. expands its international licensing with Gravity Pharma, adding Turkey for FOCUSfactor® distribution, generating $2 million in revenue.
Quiver AI Summary
Synergy CHC Corp. announced the expansion of its international licensing agreement with Gravity Pharma to include Turkey, in addition to the UAE, for exclusive distribution of its FOCUSfactor® brand. This expansion is expected to generate $2 million in upfront licensing revenue, along with performance-based royalties from product sales in these growing markets. CEO Jack Ross emphasized that this move signifies effective execution of their growth strategy, allowing the company to enhance its global brand presence without sacrificing ownership or operational focus in the U.S. The licensing model positions Synergy to tap into the expanding brain health market, projected to exceed $20 billion by 2030, while maintaining complete ownership of its intellectual property. Recent leadership additions from Coca-Cola's global beverage team further support Synergy's commitment to strategic growth and operational excellence.
Potential Positives
- Expansion of international licensing deal with Gravity Pharma to include Turkey, enhancing market presence.
- Secured $2 million in upfront licensing revenue, providing immediate financial benefits.
- Retained 100% ownership and global intellectual property, allowing for focused growth without diluting control.
- Strategic entry into the rapidly growing brain health market, projected to exceed $20 billion by 2030.
Potential Negatives
- Expansion into new markets such as Turkey may indicate that existing markets are not performing as strongly as anticipated.
- Dependence on performance-based royalties creates uncertainty in revenue, as it is contingent on sales performance in local markets.
- The focus on asset-light growth strategies could raise concerns about the company's ability to maintain quality control and brand integrity in new markets.
FAQ
What recent expansion has Synergy CHC Corp. announced?
Synergy CHC Corp. has expanded its international licensing deal with Gravity Pharma to include Turkey for FOCUSfactor® distribution.
What is the total upfront licensing revenue from the deal?
The total upfront licensing revenue from the expanded deal amounts to $2 million.
How does the licensing model benefit Synergy's ownership?
Synergy retains 100% ownership and global IP, allowing them to grow without diluting ownership or diverting operational focus.
What is the expected growth of the brain health market?
The brain health market is expected to exceed $20 billion by 2030, indicating significant growth potential.
Who is the CEO of Synergy CHC Corp.?
The CEO of Synergy CHC Corp. is Jack Ross, who emphasizes the execution of the company’s growth strategies.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SNYR Insider Trading Activity
$SNYR insiders have traded $SNYR stock on the open market 84 times in the past 6 months. Of those trades, 84 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $SNYR stock by insiders over the last 6 months:
- JACK ROSS (CEO and Chairman) has made 84 purchases buying 54,300 shares for an estimated $154,752 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Full Release
WESTBROOK, Maine, June 18, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR ) (“Synergy” or the “Company”), a fast-growing consumer health and wellness company, announced today that it has expanded its international licensing deal with Gravity Pharma , adding Turkey alongside the United Arab Emirates UAE for exclusive distribution of FOCUSfactor® . This move brings total upfront licensing revenue to $2 million , with additional performance-based royalties tied to product sales across both high-growth markets.
"This isn’t just an expansion—it’s execution," said Jack Ross , CEO of Synergy CHC Corp. “Adding Turkey alongside the United Arab Emirates (UAE), compounds our momentum and unlocks untapped growth in scalable, capital-efficient markets. We’re building brand equity globally without the overhead—exactly how growth should look in 2025.”
The UAE-Turkey licensing model allows Synergy to scale the FOCUSfactor® brand—including brain health supplements, cognitive beverages, and energy shots —without diluting ownership or diverting U.S.-based operational focus. Synergy retains 100% ownership and global IP , with performance-based royalties driving long-term upside.
Key Highlights for Investors:
- $2M in licensing secured
- Additional revenue potential through royalties
- Scalable, asset-light growth strategy
- Brain health market expected to top $20B by 2030
With global demand for cognitive health solutions surging and strategic distribution partnerships now active, SNYR is well-positioned to capitalize on both brand strength and macro health trends. These developments follow key leadership hires from Coca-Cola’s global beverage team , reinforcing the Company’s commitment to accelerated growth and operational precision.
About Synergy CHC Corp.
Synergy CHC Corp.
(NASDAQ:
SNYR
) is a next-generation consumer health and wellness company. Its flagship brands include
FOCUSfactor®
, a clinically tested brain health supplement, and
Flat Tummy®
, a lifestyle wellness brand for women. Synergy is executing a high-margin, global expansion strategy across functional health categories through capital-efficient partnerships.
Investor Relations
Gateway Group
Cody Slach, Greg Robles
949.574.3860
[email protected]
